drugset / Trial / NCT03393117

Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction

NCT03393117

RandomizedParallel-groupSingle-blindSupportive care

Summary

The purpose of this study is to determine the most effective way to control post-operative breast pain for patients undergoing a unilateral, immediate breast reconstruction.

Timeline

Start
2018-03-30
Primary completion
2020-07-01
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.25 % Other
Subject Bupivacaine Other / unclassified 266 mg Other
Background Hydromorphone Other / unclassified
Background Morphine Other / unclassified

Indications